Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and epstein-barr virus EBNA3C protein: A novel approach for immunotherapy

Human Gene Therapy

Volumn 13, Issue 7, 2002, Pages 855-866

  Hamel, Yamina ^a   Blake, Neil ^b   Gabrielsson, Susanne ^c   Haigh, Tracey ^b   Jooss, Karin ^d   Martinache, Chantal ^a   Caillat Zucman, Sophie ^a   Rickinson, Alan B ^b   Hacein Bey, Salima ^a   Fischer, Alain ^a   Cavazzana Calvo, Marina ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c INSTITUT CURIE   (France)

^d GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; PROTEIN EBNA3C; PROTEIN PP65; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL KILLING; CELL POPULATION; CELL SPECIFICITY; CELL STIMULATION; CODING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR; EPSTEIN BARR VIRUS; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; TRANSPLANTATION; VACCINIA VIRUS; VIRUS CAPSID; VIRUS CULTURE; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS STRAIN;

ADENOVIRIDAE; CELL SEPARATION; DENDRITIC CELLS; FIBROBLASTS; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; PHOSPHOPROTEINS; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSDUCTION, GENETIC; VIRAL MATRIX PROTEINS;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; VACCINIA VIRUS;

EID: 0036256802     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252899028     Document Type: Article

References (45)

1. + T cells by dendritic cells
2. A comparison of gene transfer methods in human dendritic cells
3. Phylogenetic relationships among adenovirus serotypes
4. Dendritic cells and the control of immunity
5. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
6. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
7. + T cells
8. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
9. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
10. Genetic predisposition to IDDM
11. Immune responses to adenovirus and adeno-associated virus in humans
12. Respiratory viral infections in primary immune deficiencies: Significance and relevance to clinical outcome in a single BMT unit
13. High efficiency adenovirus-mediated gene transfer to human dendritic cells
14. Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or au-tologous serum: Influence of extra-cellular pH
15. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
16. Characterization of human proliferative T cell responses to adenovirus
17. Increased frequencies of allergen-induced interleukin-13-producin g cells in atopic individuals during the pollen season
18. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset
19. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease
20. Adenovirus infections in hematopoietic stem cell transplant recipients
21. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation
22. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
23. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
24. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
25. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
26. Viral infections in children undergoing hematopoietic stem cell transplant
27. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
28. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients
29. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity
30. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro
31. Identification of target antigens for the human cytotoxic T cell response to Ep-stein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
32. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
33. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: A tool to study the fine specificity of the antiviral response
34. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
35. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
36. + T-helper and a T-killer cell
37. Infusion of cy-totoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
38. Factors influencing recombinant adeno-associated virus production
39. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts
40. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro
41. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
42. +, interferon-γ-secreting, T lymphocytes
43. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
44. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
45. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL